Loading…
Stability of cryopreserved white blood cells (WBCs) prepared for donor WBC infusions
BACKGROUND: White blood cells (WBCs) collected from hematopoietic stem cell transplant donors are often given to the recipient to speed immune recovery or treat disease relapse. The postthaw recovery and viability of cryopreserved donor WBCs, stored for as long as 7 years, were assessed. STUDY DESIG...
Saved in:
Published in: | Transfusion (Philadelphia, Pa.) Pa.), 2011-12, Vol.51 (12), p.2647-2655 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c5190-686879706ec5ab36df99befbd0ae18ea71ce90200930d4d0bd26b79af9f3c3423 |
---|---|
cites | cdi_FETCH-LOGICAL-c5190-686879706ec5ab36df99befbd0ae18ea71ce90200930d4d0bd26b79af9f3c3423 |
container_end_page | 2655 |
container_issue | 12 |
container_start_page | 2647 |
container_title | Transfusion (Philadelphia, Pa.) |
container_volume | 51 |
creator | Stroncek, David F. Xing, Lu Chau, Quyen Zia, Nausheen McKelvy, Alyce Pracht, Leigh Sabatino, Marianna Jin, Ping |
description | BACKGROUND: White blood cells (WBCs) collected from hematopoietic stem cell transplant donors are often given to the recipient to speed immune recovery or treat disease relapse. The postthaw recovery and viability of cryopreserved donor WBCs, stored for as long as 7 years, were assessed.
STUDY DESIGN AND METHODS: Total nucleated cell (TNC) cell recovery, CD3+ cell recovery, and TNC viability were measured in 311 clinical donor WBC products: 168 products were unmanipulated or minimally manipulated and 143 products were extensively manipulated. An additional 45 products were selected because they were stored for a longer duration; these were tested using both standard methods and global transcriptional analysis. All products were cryopreserved in 5% dimethyl sulfoxide (DMSO) plus 6% pentastarch and stored in liquid nitrogen.
RESULTS: The mean duration of storage of the 311 products was 143 days. Their TNC recovery was 92 ± 17%, CD3+ cell recovery was 76 ± 19%, and the TNC viability was 84 ± 6%. Duration of storage had no effect on TNC recovery, CD3+ cell recovery, or TNC viability of the 311 products. The mean duration of storage of the long‐term stored products was 5.2 years; their TNC recovery (93 ± 14%) and the TNC viability (78 ± 13%) did not differ from the 311 products, but their CD3 cell recovery was greater (86 ± 22%; p = 0.0042). Gene expression profiles of the long‐term‐stored products revealed no differences due to storage duration.
CONCLUSIONS: Donor WBC products cryopreserved in 5% DMSO and 6% pentastarch can be stored in liquid nitrogen for at least 7 years. |
doi_str_mv | 10.1111/j.1537-2995.2011.03210.x |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_911939468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1399903100</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5190-686879706ec5ab36df99befbd0ae18ea71ce90200930d4d0bd26b79af9f3c3423</originalsourceid><addsrcrecordid>eNqNkM1uEzEURi0EomnhFZA3iHYx4V4783MXLGhEC1IFggZV6sbyzNjCYTIO9oQmb4-HhLBDeGFb-s5nXx3GOMIU03q9nGIuy0wQ5VMBiFOQImXbR2xyDB6zCcAMM0QpTthpjEsAEAT4lJ0ILPIKcpywxe2ga9e5Yce95U3Y-XUw0YSfpuUP39xgeN153_LGdF3k53eX83jBE7LWIRHWB976Pu0p4K63m-h8H5-xJ1Z30Tw_nGfs69W7xfx9dvPp-sP87U3W5EiQFVVRlVRCYZpc17JoLVFtbN2CNlgZXWJjCAQASWhnLdStKOqStCUrGzkT8oy92r-7Dv7HxsRBrVwcJ9W98ZuoCJEkzYoqkef_JFESEUgESGi1R5vgYwzGqnVwKx12CkGN9tVSjZLVKFmN9tVv-2qbqi8Ov2zqlWmPxT-6E_DyAOjY6M4G3Tcu_uVyKVFQmbg3e-7BdWb33wOoxZer8Zb62b7v4mC2x74O31VRyjJXdx-v1b2gy_sF3qrP8hd_hK4n</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1399903100</pqid></control><display><type>article</type><title>Stability of cryopreserved white blood cells (WBCs) prepared for donor WBC infusions</title><source>Wiley</source><creator>Stroncek, David F. ; Xing, Lu ; Chau, Quyen ; Zia, Nausheen ; McKelvy, Alyce ; Pracht, Leigh ; Sabatino, Marianna ; Jin, Ping</creator><creatorcontrib>Stroncek, David F. ; Xing, Lu ; Chau, Quyen ; Zia, Nausheen ; McKelvy, Alyce ; Pracht, Leigh ; Sabatino, Marianna ; Jin, Ping</creatorcontrib><description>BACKGROUND: White blood cells (WBCs) collected from hematopoietic stem cell transplant donors are often given to the recipient to speed immune recovery or treat disease relapse. The postthaw recovery and viability of cryopreserved donor WBCs, stored for as long as 7 years, were assessed.
STUDY DESIGN AND METHODS: Total nucleated cell (TNC) cell recovery, CD3+ cell recovery, and TNC viability were measured in 311 clinical donor WBC products: 168 products were unmanipulated or minimally manipulated and 143 products were extensively manipulated. An additional 45 products were selected because they were stored for a longer duration; these were tested using both standard methods and global transcriptional analysis. All products were cryopreserved in 5% dimethyl sulfoxide (DMSO) plus 6% pentastarch and stored in liquid nitrogen.
RESULTS: The mean duration of storage of the 311 products was 143 days. Their TNC recovery was 92 ± 17%, CD3+ cell recovery was 76 ± 19%, and the TNC viability was 84 ± 6%. Duration of storage had no effect on TNC recovery, CD3+ cell recovery, or TNC viability of the 311 products. The mean duration of storage of the long‐term stored products was 5.2 years; their TNC recovery (93 ± 14%) and the TNC viability (78 ± 13%) did not differ from the 311 products, but their CD3 cell recovery was greater (86 ± 22%; p = 0.0042). Gene expression profiles of the long‐term‐stored products revealed no differences due to storage duration.
CONCLUSIONS: Donor WBC products cryopreserved in 5% DMSO and 6% pentastarch can be stored in liquid nitrogen for at least 7 years.</description><identifier>ISSN: 0041-1132</identifier><identifier>EISSN: 1537-2995</identifier><identifier>DOI: 10.1111/j.1537-2995.2011.03210.x</identifier><identifier>PMID: 21658051</identifier><identifier>CODEN: TRANAT</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Blood Donors ; Blood Preservation ; Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Cryopreservation ; Dimethyl Sulfoxide - chemistry ; Female ; Humans ; Hydroxyethyl Starch Derivatives - chemistry ; Leukocyte Transfusion ; Leukocytes - cytology ; Male ; Medical sciences ; Time Factors ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>Transfusion (Philadelphia, Pa.), 2011-12, Vol.51 (12), p.2647-2655</ispartof><rights>2011 American Association of Blood Banks</rights><rights>2015 INIST-CNRS</rights><rights>2011 American Association of Blood Banks.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5190-686879706ec5ab36df99befbd0ae18ea71ce90200930d4d0bd26b79af9f3c3423</citedby><cites>FETCH-LOGICAL-c5190-686879706ec5ab36df99befbd0ae18ea71ce90200930d4d0bd26b79af9f3c3423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25331297$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21658051$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stroncek, David F.</creatorcontrib><creatorcontrib>Xing, Lu</creatorcontrib><creatorcontrib>Chau, Quyen</creatorcontrib><creatorcontrib>Zia, Nausheen</creatorcontrib><creatorcontrib>McKelvy, Alyce</creatorcontrib><creatorcontrib>Pracht, Leigh</creatorcontrib><creatorcontrib>Sabatino, Marianna</creatorcontrib><creatorcontrib>Jin, Ping</creatorcontrib><title>Stability of cryopreserved white blood cells (WBCs) prepared for donor WBC infusions</title><title>Transfusion (Philadelphia, Pa.)</title><addtitle>Transfusion</addtitle><description>BACKGROUND: White blood cells (WBCs) collected from hematopoietic stem cell transplant donors are often given to the recipient to speed immune recovery or treat disease relapse. The postthaw recovery and viability of cryopreserved donor WBCs, stored for as long as 7 years, were assessed.
STUDY DESIGN AND METHODS: Total nucleated cell (TNC) cell recovery, CD3+ cell recovery, and TNC viability were measured in 311 clinical donor WBC products: 168 products were unmanipulated or minimally manipulated and 143 products were extensively manipulated. An additional 45 products were selected because they were stored for a longer duration; these were tested using both standard methods and global transcriptional analysis. All products were cryopreserved in 5% dimethyl sulfoxide (DMSO) plus 6% pentastarch and stored in liquid nitrogen.
RESULTS: The mean duration of storage of the 311 products was 143 days. Their TNC recovery was 92 ± 17%, CD3+ cell recovery was 76 ± 19%, and the TNC viability was 84 ± 6%. Duration of storage had no effect on TNC recovery, CD3+ cell recovery, or TNC viability of the 311 products. The mean duration of storage of the long‐term stored products was 5.2 years; their TNC recovery (93 ± 14%) and the TNC viability (78 ± 13%) did not differ from the 311 products, but their CD3 cell recovery was greater (86 ± 22%; p = 0.0042). Gene expression profiles of the long‐term‐stored products revealed no differences due to storage duration.
CONCLUSIONS: Donor WBC products cryopreserved in 5% DMSO and 6% pentastarch can be stored in liquid nitrogen for at least 7 years.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Blood Donors</subject><subject>Blood Preservation</subject><subject>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Cryopreservation</subject><subject>Dimethyl Sulfoxide - chemistry</subject><subject>Female</subject><subject>Humans</subject><subject>Hydroxyethyl Starch Derivatives - chemistry</subject><subject>Leukocyte Transfusion</subject><subject>Leukocytes - cytology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Time Factors</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0041-1132</issn><issn>1537-2995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqNkM1uEzEURi0EomnhFZA3iHYx4V4783MXLGhEC1IFggZV6sbyzNjCYTIO9oQmb4-HhLBDeGFb-s5nXx3GOMIU03q9nGIuy0wQ5VMBiFOQImXbR2xyDB6zCcAMM0QpTthpjEsAEAT4lJ0ILPIKcpywxe2ga9e5Yce95U3Y-XUw0YSfpuUP39xgeN153_LGdF3k53eX83jBE7LWIRHWB976Pu0p4K63m-h8H5-xJ1Z30Tw_nGfs69W7xfx9dvPp-sP87U3W5EiQFVVRlVRCYZpc17JoLVFtbN2CNlgZXWJjCAQASWhnLdStKOqStCUrGzkT8oy92r-7Dv7HxsRBrVwcJ9W98ZuoCJEkzYoqkef_JFESEUgESGi1R5vgYwzGqnVwKx12CkGN9tVSjZLVKFmN9tVv-2qbqi8Ov2zqlWmPxT-6E_DyAOjY6M4G3Tcu_uVyKVFQmbg3e-7BdWb33wOoxZer8Zb62b7v4mC2x74O31VRyjJXdx-v1b2gy_sF3qrP8hd_hK4n</recordid><startdate>201112</startdate><enddate>201112</enddate><creator>Stroncek, David F.</creator><creator>Xing, Lu</creator><creator>Chau, Quyen</creator><creator>Zia, Nausheen</creator><creator>McKelvy, Alyce</creator><creator>Pracht, Leigh</creator><creator>Sabatino, Marianna</creator><creator>Jin, Ping</creator><general>Blackwell Publishing Inc</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>201112</creationdate><title>Stability of cryopreserved white blood cells (WBCs) prepared for donor WBC infusions</title><author>Stroncek, David F. ; Xing, Lu ; Chau, Quyen ; Zia, Nausheen ; McKelvy, Alyce ; Pracht, Leigh ; Sabatino, Marianna ; Jin, Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5190-686879706ec5ab36df99befbd0ae18ea71ce90200930d4d0bd26b79af9f3c3423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Blood Donors</topic><topic>Blood Preservation</topic><topic>Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Cryopreservation</topic><topic>Dimethyl Sulfoxide - chemistry</topic><topic>Female</topic><topic>Humans</topic><topic>Hydroxyethyl Starch Derivatives - chemistry</topic><topic>Leukocyte Transfusion</topic><topic>Leukocytes - cytology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Time Factors</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stroncek, David F.</creatorcontrib><creatorcontrib>Xing, Lu</creatorcontrib><creatorcontrib>Chau, Quyen</creatorcontrib><creatorcontrib>Zia, Nausheen</creatorcontrib><creatorcontrib>McKelvy, Alyce</creatorcontrib><creatorcontrib>Pracht, Leigh</creatorcontrib><creatorcontrib>Sabatino, Marianna</creatorcontrib><creatorcontrib>Jin, Ping</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transfusion (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stroncek, David F.</au><au>Xing, Lu</au><au>Chau, Quyen</au><au>Zia, Nausheen</au><au>McKelvy, Alyce</au><au>Pracht, Leigh</au><au>Sabatino, Marianna</au><au>Jin, Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stability of cryopreserved white blood cells (WBCs) prepared for donor WBC infusions</atitle><jtitle>Transfusion (Philadelphia, Pa.)</jtitle><addtitle>Transfusion</addtitle><date>2011-12</date><risdate>2011</risdate><volume>51</volume><issue>12</issue><spage>2647</spage><epage>2655</epage><pages>2647-2655</pages><issn>0041-1132</issn><eissn>1537-2995</eissn><coden>TRANAT</coden><abstract>BACKGROUND: White blood cells (WBCs) collected from hematopoietic stem cell transplant donors are often given to the recipient to speed immune recovery or treat disease relapse. The postthaw recovery and viability of cryopreserved donor WBCs, stored for as long as 7 years, were assessed.
STUDY DESIGN AND METHODS: Total nucleated cell (TNC) cell recovery, CD3+ cell recovery, and TNC viability were measured in 311 clinical donor WBC products: 168 products were unmanipulated or minimally manipulated and 143 products were extensively manipulated. An additional 45 products were selected because they were stored for a longer duration; these were tested using both standard methods and global transcriptional analysis. All products were cryopreserved in 5% dimethyl sulfoxide (DMSO) plus 6% pentastarch and stored in liquid nitrogen.
RESULTS: The mean duration of storage of the 311 products was 143 days. Their TNC recovery was 92 ± 17%, CD3+ cell recovery was 76 ± 19%, and the TNC viability was 84 ± 6%. Duration of storage had no effect on TNC recovery, CD3+ cell recovery, or TNC viability of the 311 products. The mean duration of storage of the long‐term stored products was 5.2 years; their TNC recovery (93 ± 14%) and the TNC viability (78 ± 13%) did not differ from the 311 products, but their CD3 cell recovery was greater (86 ± 22%; p = 0.0042). Gene expression profiles of the long‐term‐stored products revealed no differences due to storage duration.
CONCLUSIONS: Donor WBC products cryopreserved in 5% DMSO and 6% pentastarch can be stored in liquid nitrogen for at least 7 years.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>21658051</pmid><doi>10.1111/j.1537-2995.2011.03210.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-1132 |
ispartof | Transfusion (Philadelphia, Pa.), 2011-12, Vol.51 (12), p.2647-2655 |
issn | 0041-1132 1537-2995 |
language | eng |
recordid | cdi_proquest_miscellaneous_911939468 |
source | Wiley |
subjects | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Blood Donors Blood Preservation Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis Bone marrow, stem cells transplantation. Graft versus host reaction Cryopreservation Dimethyl Sulfoxide - chemistry Female Humans Hydroxyethyl Starch Derivatives - chemistry Leukocyte Transfusion Leukocytes - cytology Male Medical sciences Time Factors Transfusions. Complications. Transfusion reactions. Cell and gene therapy |
title | Stability of cryopreserved white blood cells (WBCs) prepared for donor WBC infusions |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A01%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stability%20of%20cryopreserved%20white%20blood%20cells%20(WBCs)%20prepared%20for%20donor%20WBC%20infusions&rft.jtitle=Transfusion%20(Philadelphia,%20Pa.)&rft.au=Stroncek,%20David%20F.&rft.date=2011-12&rft.volume=51&rft.issue=12&rft.spage=2647&rft.epage=2655&rft.pages=2647-2655&rft.issn=0041-1132&rft.eissn=1537-2995&rft.coden=TRANAT&rft_id=info:doi/10.1111/j.1537-2995.2011.03210.x&rft_dat=%3Cproquest_cross%3E1399903100%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5190-686879706ec5ab36df99befbd0ae18ea71ce90200930d4d0bd26b79af9f3c3423%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1399903100&rft_id=info:pmid/21658051&rfr_iscdi=true |